Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Workforce, the Judiciary, Armed Services, Veterans' Affairs, and Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 8324: To amend the Internal Revenue Code of 1986 to increase the limitations on contributions to health savings accounts, to amend the Public Health Service Act to provide for hospital and insurer price transparency, and for other purposes.”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 8319: To amend title XVIII of the Social Security Act to expand certain remote monitoring services furnished by physicians to individuals with end stage renal disease under the Medicare program.”

Ordered to be Reported by the Yeas and Nays: 41 - 2.

Original title: “HR 7654: Advance Global Health Act”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 7417: Women’s Heart Health Expansion Act of 2026”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 8260: Cardiovascular Disease Early Detection and Prevention Act of 2026”

Referred to the House Committee on Education and Workforce.

Original title: “HR 8279: To expand the definition of institution of higher education in the Higher Education Act of 1965 with respect to certain graduate medical schools located outside of the United States.”

The Food and Drug Administration (FDA or the Agency) is announcing the issuance of four Emergency Use Authorizations (EUA) (Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products. FDA has issued three EUAs for animal products as requested by Boehringer Ingelheim Animal Health USA, Inc. (Boehringer) for the prevention of infestations caused by New World screwworm (Cochliomyia hominivorax) (NWS) larvae (myiasis) in certain cattle, and for the treatment of

Original title: “Authorization of Emergency Use for Four Animal Drugs for the Treatment of New World Screwworm; Availability”

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Animal Drug User Fee Act." The purpose of the public meeting is to invite public comment on the Animal Drug User Fee Act (ADUFA) program and suggestions regarding the features FDA should consider for the next reauthorization of the ADUFA program. The meeting will be open to the public.

Original title: “Animal Drug User Fee Act; Public Meeting; Request for Comments”

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled "Animal Generic Drug User Fee Act." The purpose of the public meeting is to invite public comment on the Animal Generic Drug User Fee Act (AGDUFA) program and suggestions regarding the features FDA should consider for the next reauthorization of the AGDUFA program. The meeting will be open to the public.

Original title: “Animal Generic Drug User Fee Act; Public Meeting; Request for Comments”

The Office of Planning, Research, and Evaluation (OPRE) and the Family and Youth Services Bureau (FYSB) in the Administration for Children and Families (ACF) request approval for a revision to a currently approved information collection activity as part of the Personal Responsibility Education Program (PREP) Performance Measures project (Office of Management and Budget (OMB) #: 0970-0497; expiration date July 31, 2026). The goal of the project is to collect, analyze, and report on performance me

Original title: “Proposed Information Collection Activity; Personal Responsibility Education Program (PREP) Performance Measures”

Erica Schwartz, a former deputy surgeon general and member of the U.S. military, will take over from what has amounted to a rapid succession of CDC leaders over the past year.

Original title: “Trump nominates new CDC director, appoints various leaders to embattled agency”

If confirmed by the Senate, Schwartz could finally fill a void for an agency that’s cycled through multiple leaders over the last year.

Original title: “Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director”

With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns.

Original title: “FDA mulls compounding for peptides previously flagged over safety risks”

The agency’s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he’s a “big fan” of peptides.

Original title: “FDA moves toward easing restrictions on certain peptides”